PGTai™ Technology Platform

A revolutionary approach to PGT-A analysis
more euploids, more confidence, more transfers
The PGTai technology platform empowers clinicians and patients

The PGTai platform is our revolutionary approach to PGT-A providing clinicians greater confidence in their embryo transfer decisions.
The PGTai platform has been able to provide the following:

- More euploid embryos reported
- Increase in number of patients with at least one reported euploid embryo
- Reported an extra 1300+ euploid embryos as a result of this innovation*
- Most innovative and robust test in the market
- Only platform in the field built on live births and sustained pregnancy outcomes

More euploids, more confidence, more transfers

*CooperSurgical internal data: prior (subjective) methodology, Jan 1, 2018 through Nov 1, 2018 vs PGTai technology platform, Nov 2, 2018 through May 31, 2019
More euploid embryos

The PGTai platform increases the rates of the number of euploid embryos reported

In the first seven months of reporting results through the PGTai platform, we have reported more euploid embryos, thus providing clinicians with greater transfer opportunities.

- **7.7% relative increase in euploid embryo reporting**
- **21.2% relative decrease in mosaic embryo reporting**
- **4.2% relative decrease in aneuploid embryo reporting**

**Examples of reported ploidy rates using prior methodology/subjective interpretation vs the PGTai platform**

Sample sizes are shown alongside the data bars in the format (n=prior [subjective] methodology:PGTai platform)
Comparison of several clinics and their classification rates using prior methodology/subjective interpretation vs the PGTai platform

The overall increase in euploid rates is observed across all age ranges, as is the decrease in mosaic and aneuploid rates.

**Clinic A**

CooperSurgical internal data: prior (subjective) methodology, Jan 1, 2018 through Nov 1, 2018 vs PGTai technology platform, Nov 2, 2018 through May 31, 2019

**Clinic B**

With prior (subjective) methodology
- **Euploid Rates**
- **Mosaic Rates**
- **Aneuploid Rates**

With the PGTai Platform
- **Euploid Rates**
- **Mosaic Rates**
- **Aneuploid Rates**
More patients with at least one euploid embryo

Since the launch of the PGTai platform, we have also observed an increase in the percentage of patients reported with at least one euploid embryo, providing patients of all age ranges with a greater chance at a euploid embryo transfer.

Patients with at least one euploid embryo reported using prior methodology/subjective interpretation vs the PGTai platform

Sample sizes are shown alongside the data bars in the format (n=prior [subjective] methodology:PGTai platform)
Since the launch of the PGTai platform, we have also observed an increase in the percentage of patients reported with at least one euploid embryo, providing patients of all age ranges with a greater chance at a euploid embryo transfer.

More than 1300 extra euploid embryos reported

We have reported an extra 1300+ euploid embryos as a result of the PGTai platform, which previously would have been reported as aneuploid or mosaic.

Net change observed in ploidy classification using prior methodology/subjective interpretation vs the PGTai platform

Egg Donor

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Euploid Rates</th>
<th>Aneuploid Rates</th>
<th>Mosaic Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Ages</td>
<td>-3.8%</td>
<td>+5.8%</td>
<td></td>
</tr>
<tr>
<td>Egg Donor</td>
<td>-3.4%</td>
<td>+3.5%</td>
<td></td>
</tr>
<tr>
<td>&lt;35</td>
<td>-5.6%</td>
<td>+6.9%</td>
<td></td>
</tr>
<tr>
<td>35-37</td>
<td>-3.6%</td>
<td>+5.2%</td>
<td></td>
</tr>
<tr>
<td>38-40</td>
<td>-3.3%</td>
<td>+4.2%</td>
<td></td>
</tr>
<tr>
<td>41-42</td>
<td>-1.4%</td>
<td>+2.9%</td>
<td></td>
</tr>
<tr>
<td>&gt;42</td>
<td>-2.6%</td>
<td>+3.5%</td>
<td></td>
</tr>
</tbody>
</table>

Data pooled from representative clinics

CooperSurgical internal data: prior (subjective) methodology, Jan 1, 2018 through Nov 1, 2018 vs PGTai technology platform, Nov 2, 2018 through May 31, 2019
A revolution in PGT-A analysis

The PGTai technology platform is the most innovative and robust test in the market and the only platform in the market built from live births and sustained pregnancy outcomes.

Over the years, advances in technology have played a pivotal role in the evolution of PGT. These technological innovations have driven improvements in accuracy, sensitivity and specificity of PGT-A results.

We are proud to be driving the next leap in PGT-A technology. The PGTai platform is a ground-breaking algorithm that harnesses the power of big data using a massive reference set to maximize PGT-A calling, interpretation and reporting.
Key features of the PGTai technology platform

- Innovative tool that leverages the data accumulated over the history of PGT-A at CooperGenomics
- Only analysis platform in the field built from a truth data set of live births and sustained pregnancy outcomes
- Allows transfer decisions based on mathematical and statistical predictions, minimizing human interaction, subjectivity and error
- Employs machine learning to enable continuous controlled improvement
- Improves signal clarity, to increase accuracy and ensure optimal sensitivity and specificity

The PGTai platform brings the power of big data to the clinician’s transfer decisions

- Removes human subjectivity
- Avoids human errors
At CARE Fertility, we have been impressed with the transition from standard to PGTai; the staff education and clarity of reporting. In addition, we are reassured by the increased precision of this test and believe it brings benefits for our patients.

Alison Campbell
Director of Embryology, CARE Fertility Group, London, UK

The switch to PGTai has more than halved the turnaround time on our results, with the lab now averaging 3 days from sample receipt to providing us with the final report. That’s been an enormous benefit, those extra few days waiting for results make a huge difference to our patients!

We’ve seen a drop in the number of ‘no call’ results since the changeover to below 2%. Most importantly the level of service from the staff we deal with in the UK laboratory has been outstanding, always friendly, helpful and on top of anything we need.

Kelli Sorby
Scientific Director, Number1 Fertility, Melbourne, Australia
# How the PGTai technology platform is revolutionizing PGT-A

<table>
<thead>
<tr>
<th></th>
<th>CooperGenomics PGTai</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Algorithm built on/validated on</td>
<td>&gt;1,000/&gt;10,000</td>
<td>~100/?</td>
</tr>
<tr>
<td>Modeled on live births and sustained pregnancy outcomes</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Detects mosaicism</td>
<td>✓, 20-80%</td>
<td>Some, varies</td>
</tr>
<tr>
<td>Removes human subjectivity</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Minimizes human (interpretation &amp; transcription) error</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Platform</td>
<td>Custom/Dynamic</td>
<td>Off the shelf/ Static</td>
</tr>
<tr>
<td>Can be performed without ICSI</td>
<td>✓</td>
<td>Some</td>
</tr>
</tbody>
</table>

By providing clinicians and patients with an increased number of euploid embryos available for transfer, PGTai technology is impacting pregnancy rates.

*More euploids, more confidence, more transfers*

CooperSurgical internal data: prior (subjective) methodology, Jan 1, 2018 through Nov 1, 2018 vs PGTai technology platform, Nov 2, 2018 through May 31, 2019
A solution as unique as your business

At CooperSurgical, we partner with you to drive clinical efficiency

When you partner with CooperSurgical you become part of a truly global network of clinical experts ready to support you with highly specialized solutions, both for individual clinics and across large organizations. By providing you with optimal products, services and training our aim is to offer you the best possible support to drive the efficiency of your clinic — and achieve the best results.

* Day-to-day delivery may vary according to geographical location